Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Auric Goldfinger's Short List -- Ignore unavailable to you. Want to Upgrade?

To: Pancho Villa who wrote (803)	11/23/1998 10:53:00 PM
From: Sir Auric Goldfinger	Read Replies (1) \| Respond to of 19428

Funnily enough, the Salomon Smith Barney analyst thinks that IMNX will have 5,000 Rx's by year end. Me thinks not. A lot of Dr's on vacation already and this stuff costs $1,200/year.

To: Pancho Villa who wrote (803)	11/24/1998 10:26:00 AM
From: Sir Auric Goldfinger	Respond to of 19428

Immunex CFO:'Hard To Tell' If Stock Is Ahead Of Itself>IMNX 11/23/98 18:23 NEW YORK (Dow Jones)--Immunex Corp.'s (IMNX) chief financial officer, Doug Southern, said it is "hard to tell" if the company's stock price is ahead of itself after setting a 52-week high Monday. Two weeks ago, Immunex received Food and Drug Administration approval for use of its Enbrel rheumatoid arthritis treatment in adults. The biotechnology company's shares began to gain ground on the news and were further bolstered by a study that found that Enbrel was also effective in treating juveniles with the disease. In an interview with CNBC Monday, Southern said Enbrel "is a major step forward for our company." He explained that the rheumatoid arthritis treatment market is "a very large market and probably more importantly, it's an underserved market." The executive said he expects the drug to have a relatively slow uptake as compared with drugs that are sold through wholeslae distribution channels. He added that the company will have a better idea of how much the drug will add to Immunex's sales by the end of the first quarter. Southern did note that the company expects to be profitable in the fourth quarter. Immunex's shares closed at 92 Monday, up 5 1/8, or 5.9%. Earlier, the shares reached 94 7/8, eclipsing the previous 52-week high of 91 7/8 set Thursday. - Nicole Ridgway; 201-938-5174 (END) DOW JONES NEWS 11-23-98 06:23 PM - - 06 23 PM EST 11-23-98